Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05507541
Title	TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Mayo Clinic
Indications	diffuse large B-cell lymphoma activated B-cell type primary mediastinal B-cell lymphoma B-cell lymphoma diffuse large B-cell lymphoma germinal center B-cell type high-grade B-cell lymphoma double-hit/triple-hit diffuse large B-cell lymphoma follicular lymphoma
Therapies	Pembrolizumab + TTI-622 Pembrolizumab + TTI-621
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University of Iowa	RECRUITING	Iowa City	Iowa	52242	United States	Details
Mayo Clinic	RECRUITING	Rochester	Minnesota	55905	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field